Nektar Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026.

Key Highlights

  • Shares outstanding: The company reported 34,214,683 shares of common stock, $0.0001 par value, outstanding as of November 6, 2026.
  • Filer classification: Nektar Therapeutics is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Key pipeline asset: The filing identifies rezpegaldesleukin (previously referred to as NKTR-358) as the company's primary drug candidate, noting the business would be "significantly harmed" if it does not continue to advance in clinical studies.
  • Shell company status: The registrant indicated it is not a shell company as defined by Rule 12b-2 of the Exchange Act.
  • Exchange listing: Common stock is listed on the Nasdaq Capital Market under the symbol NKTR.

Nektar's Third-Quarter 2026 Filing: Pipeline Focus and Risk Disclosures

Nektar Therapeutics (NASDAQ:NKTR), headquartered at 455 Mission Bay Boulevard South, San Francisco, California 94158, submitted its quarterly report covering the three- and nine-month periods ended September 30, 2026. The filing encompasses condensed consolidated financial statements, management's discussion and analysis, and an expanded risk factors section under Part II, Item 1A.

According to the filing, the company's primary focus remains rezpegaldesleukin, formerly referred to as NKTR-358, which the registrant describes as a drug candidate upon which the business is "highly dependent." The filing states that the company's business "will be significantly harmed if rezpegaldesleukin does not continue to advance in clinical studies." The filing also notes that outcomes from competitive immunotherapy clinical trials "could have a material and adverse impact on the value of our pipeline," reflecting the company's characterization of risks in the broader immunotherapy field.

The company disclosed a range of additional risk factors related to its research and development efforts, including the lengthy and uncertain nature of clinical drug development, dependence on third parties for laboratory experiments and preclinical studies, potential delays in clinical trials due to site activation or patient enrollment challenges, and the possibility that preliminary and interim clinical data could change materially following audit and verification procedures. The filing contains forward-looking statements, which the company notes are subject to its cautionary language and could differ materially from actual results.

What Was Disclosed

Nektar Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, reporting 34,214,683 shares outstanding as of November 6, 2026, its non-accelerated and smaller reporting company status, and extensive risk disclosures centered on its rezpegaldesleukin program.